Mechanism of PARP inhibitor resistance and potential overcoming strategies  

作　　者：Xiaoyu Fu Ping Li Qi Zhou Ruyuan He Guannan Wang Shiya Zhu Amir Bagheri Gary Kupfer Huadong Pei Juanjuan Li 

机构地区：[1]Department of Oncology,Georgetown Lombardi Comprehensive Cancer Center,Georgetown University Medical Center,Washington,DC 20057,USA [2]Department of Breast and Thyroid Surgery,Renmin Hospital of Wuhan University,Wuhan,Hubei 430060,China [3]Cancer Center,Renmin Hospital of Wuhan University,Wuhan,Hubei 430060,China [4]Department of Thoracic Surgery,Renmin Hospital of Wuhan University,Wuhan,Hubei 430060,China

出　　处：《Genes & Diseases》2024年第1期306-320,共15页基因与疾病（英文）

摘　　要：PARP inhibitors(PARPi)are a kind of cancer therapy that targets poly(ADP-ribose)polymerase.PARPi is the first clinically approved drug to exert synthetic lethality by obstruct-ing the DNA single-strand break repair process.Despite the significant therapeutic effect in pa-tients with homologous recombination(HR)repair deficiency,innate and acquired resistance to PARPi is a main challenge in the clinic.In this review,we mainly discussed the underlying mechanisms of PARPi resistance and summarized the promising solutions to overcome PARPi resistance,aiming at extending PARPi application and improving patient outcomes.

关 键 词：Drug resistance Homologous recombination PARP PARP inhibitor Poly(ADP-ribose)polymerase 

分 类 号：R97[医药卫生—药品]